Heart Files: ESC Congress Rewrites the Rules on Cholesterol, Statins, and Silent Artery Disease

The AMUNDSEN trial dropped a bombshell at ESC Congress: slamming PCSK9 inhibitors into heart attack patients during emergency catheterization slashed LDL cholesterol 82% vs. 40% for standard care — yet produced zero clinical benefit after one year. The trial of over 2,100 acute MI patients found that rapid lipid-lowering in the cath lab, while effective at dropping numbers, didn't reduce death or cardiovascular hospitalization.

Zoom Out

The ESC Congress in Munich is...